Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment

INTRODUCTION: Immune checkpoint inhibitors improved survival of advanced stage non-small cell lung cancer patients, but the overall response rate remains low. A biomarker that identifies non-responders would be helpful to allow treatment decisions. Clearance of immune checkpoint inhibitors is relate...

Descripción completa

Detalles Bibliográficos
Autores principales: Otten, Leila S., Piet, Berber, van den Haak, Demy, Schouten, Robert D., Schuurbiers, Milou, Badrising, Sushil K., Boerrigter, Emmy, Burgers, Sjaak A., ter Heine, Rob, van den Heuvel, Michel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684661/
https://www.ncbi.nlm.nih.gov/pubmed/37856040
http://dx.doi.org/10.1007/s40262-023-01316-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684661/
https://www.ncbi.nlm.nih.gov/pubmed/37856040
http://dx.doi.org/10.1007/s40262-023-01316-5

Ejemplares similares